{"entity":{"id":"paper-rosella-relacorilant-lancet-2025","kind":"paper","name":"ROSELLA: relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer","aka":[],"tldr":"Adding relacorilant, a drug that blocks the cortisol receptor and thereby restores chemotherapy sensitivity, to nab-paclitaxel lengthened progression-free and overall survival in platinum-resistant ovarian cancer regardless of any biomarker.","summary":"Phase 3 trial of 381 patients with platinum-resistant ovarian cancer and one to three prior lines randomised to intermittent relacorilant plus nab-paclitaxel or nab-paclitaxel alone.\n\nMedian progression-free survival was 6.54 versus 5.52 months (hazard ratio 0.70) and interim median overall survival 15.97 versus 11.50 months (hazard ratio 0.69), with a similar safety profile between arms.","asOf":"2026-09-17","links":[{"label":"Lancet 2025","url":"https://doi.org/10.1016/S0140-6736(25)01040-2"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/40473448/"}],"tags":[],"related":[],"cancers":["platinum-resistant-ovarian-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["relacorilant"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["rosella"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet"],"dependsOn":[],"notes":[],"journal":"The Lancet","year":2025,"doi":"10.1016/S0140-6736(25)01040-2","pmid":"40473448","authors":"Olawaiye AB, Gladieff L, O'Malley DM, et al.","paperType":"rct","findings":["Median progression-free survival 6.54 vs 5.52 months; hazard ratio 0.70.","Interim median overall survival 15.97 vs 11.50 months; hazard ratio 0.69."],"whatItMeans":"Relacorilant with nab-paclitaxel is a new option for platinum-resistant disease that does not depend on folate receptor status, with regulatory review following the trial.","caveats":["Open-label design.","Overall survival analysis was interim."],"changedPractice":true,"participants":381},"route":"/key-papers/paper-rosella-relacorilant-lancet-2025/","neighbours":{"cancer":[{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"drug":[{"id":"relacorilant","kind":"drug","name":"Relacorilant","route":"/drugs/relacorilant/"}],"trial":[{"id":"rosella","kind":"trial","name":"ROSELLA / GOG-3073","route":"/trials/rosella/"}],"journal":[{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/"}]}}